In the manuscript, we already clarified the sample size calculation in the statistical part of the methods. Basically, the number of injections in 12 months was reported as 2.32 (SD = 1.22) in the 1 + prn regimen and 3.57 (SD = 1.12) in the 3 + prn regimen based on the published results in a retrospective study. 3 Alpha was set as 0.05 for a two-side test and a power of 0.95 was used to calculate the sample size under a 1:1 randomization ratio.
Dexamethasone intravitreous implant vs bevacizumab for central retinal vein occlusion-related macular oedema: A prospective randomized comparison-Comment
We read with great interest the randomized controlled trial by Gado and Macky, presenting the outcomes of patients with central vein occlusion treated with Bevacizumab or dexamethasone implant. 1 Best corrected visual acuity (BCVA) of candidates in this study was measured at a distance of 2 m using Snellen visual acuity charts, which were converted to a logarithmic scale (logMAR) for statistical analysis. They included patients with macular oedema due to central retinal vein occlusion with best corrected visual acuity 0.3 logMAR to counting fingers. However, BCVA in baseline was showed in Figure 1 of both groups are better than 0.3 logMAR. They described significantly increase in BCVA of both drugs at 6 months. Unfortunately, Figure 1 of the Gado's article showed that both groups mean VA significantly worsened when comparing the baseline, dropping to about 0.6 log-MAR at this point. Therefore, we want to question the efficacy of these drugs on BCVA. At this point, we sincerely ask the authors perform analyses of the BCVA of these drugs. Thus, we believe that these corrected data of this study will clarify the functional outcome and comparison of these drugs on patients with CRVO-MO and these information would be a powerful guide for clinical treatment.
Dexamethasone intravitreous implant vs bevacizumab for central retinal vein occlusion related macular oedema: A prospective randomized comparison-Response
We would like to thank Li et al 1 for their interest in our work 2 and for their valuable comments. We would like to confirm that in our study, the best-corrected visual acuity (BCVA) of our patients were measured at a distance of 2 m using Snellen visual acuity charts. This visual acuity data was converted to a logarithmic scale (logMAR) only to have a better statistical analysis. We would like also to confirm that we included patients with macular oedema (MO) due to central retinal vein occlusion (CRVO) with BCVA range from 0.3 logMAR to counting fingers. However, as mentioned in the text (p. 653, last line under the title "Primary outcome measures") and in figure 1 legend (p. 653) , the visual acuity presented on vertical axis of the bar chart of Figure 1 is in decimals. We thought that visual acuities in decimals on the bar chart will be more informative and more presentable to the reader than logMARs. That means that at 6 months the mean BCVA for each group was 0.6 in decimals not 0.6 in logMARs, which is corresponding to 6/9 in Snellen and 0.2 logMARs, as mentioned in the text (p. 653), and therefore there was improvement of BCVAs, not deterioration. Hence, we would like to confirm to Li et al 1 that the data presented in the original article is correct. 2 In our study, we found that both treatment methods provided equal and effective improvement of patients' BCVA throughout the 6-month study period. There was statistically significant improvement of BCVA in both treatment groups between baseline and each study visit with corresponding central foveal thickness changes. Thus, we believe that the both intravitreal dexamethasone implant and bevacizumab injections have equal and comparable efficacy and safety in the treatment of MO secondary to CRVO.
